Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex

mTORC1 is aberrantly activated in cancer and in the genetic tumor syndrome tuberous sclerosis complex (TSC), which is caused by loss-of-function mutations in the TSC complex, a negative regulator of mTORC1. Clinically approved mTORC1 inhibitors, such as rapamycin, elicit a cytostatic effect that fai...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Molly C., Hosios, Aaron M., Torrence, Margaret E., Zhao, Ting, Fraser, Cameron, Wilkinson, Meghan, Kwiatkowski, David J., Henske, Elizabeth P., Wu, Chin-Lee, Sarosiek, Kristopher A., Valvezan, Alexander J., Manning, Brendan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663903/
https://www.ncbi.nlm.nih.gov/pubmed/36388985
http://dx.doi.org/10.1016/j.isci.2022.105458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663903/
https://www.ncbi.nlm.nih.gov/pubmed/36388985
http://dx.doi.org/10.1016/j.isci.2022.105458

Ejemplares similares